Jupiter Neurosciences正在开发一种基于白藜芦醇的独特平台产品，主要用于治疗神经炎症。公司相信其主要候选药物JOTROL，有望用于治疗多种神经和罕见疾病。JOTROL已于2021年3月完成了第一阶段的安全性和耐受性试验，Jupiter计划在IPO完成后启动第二阶段的试验。Jupiter Neurosciences plans to issue 2.8 million stocks at a price of $4 to $5 per share, raising an estimated $12 million.
Jupiter Neurosciences (JUNS.US), a biotechnology company dedicated to developing oral neuroinflammatory therapies, is currently in Phase 1 clinical trials. Last Friday, the company adjusted the terms of its upcoming initial public offering (IPO), with plans to issue 2.8 million shares of stock at a price of $4 to $5 per share, raising $12 million. At the midpoint of the new price range, the company expects to raise about 17% less than its previous plan to issue 2.6 million shares of stock at a price of $5.75 per share.
In addition, the company has replaced its sole bookrunner with Revere Securities and disclosed its latest financial data in the latest filing. It is worth noting that this is Jupiter Neurosciences' first update to its prospectus since January 2023.
Jupiter Neurosciences is developing a unique platform product based on resveratrol for the treatment of neuroinflammation. The company believes that its lead candidate drug, JOTROL, has the potential to treat a variety of neurological and rare diseases. JOTROL completed Phase 1 safety and tolerability trials in March 2021, and Jupiter plans to initiate Phase 2 trials after its IPO is completed.
Jupiter Neurosciences, founded in 2016, is seeking to list on the Nasdaq Exchange under the stock code JUNS. Revere Securities will serve as the sole bookrunner for the transaction.
